ArticleRheumatology and immunology research2022
The Challenges and Future Perspective for the Management of Systemic Lupus Erythematosus in China: A Concise Annual Report of 2020.
Article in Rheumatology and immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Peripheral Blood Neutrophil-to-Lymphocyte Ratio Combined With Fibrinogen-to-Albumin Ratio Assists in Identifying Systemic Lupus Erythematosus Activity and Lupus Nephritis.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Tofacitinib vs . glucocorticoids in mild-to-moderate systemic lupus erythematosus: A real-world study of the CSTAR cohort.Chinese medical journal · 2026Article
- Tofacitinib versus BAFF inhibitor in mild to moderate systemic lupus erythematosus: a real-world study based on CSTAR cohort.Clinical rheumatology · 2026Article
- Between Visible Marks and Invisible Pain: A Qualitative Study of Multi-Layered Stigma Among Women with Systemic Lupus Erythematosus in China.Behavioral sciences (Basel, Switzerland) · 2026Article
- Interferon-induced protein 44-like promoter Hypomethylation as an epigenetic hallmark of systemic lupus erythematosus.Journal of translational medicine · 2026Article
- Efficacy and safety of telitacicept in systemic lupus erythematosus: a single-center, retrospective, real-world study.Frontiers in immunology · 2026Article
- Effectiveness and safety of belimumab and telitacicept in active systemic lupus erythematosus: a retrospective cohort study.Frontiers in immunology · 2026Article
- Article
- Observational
- A case report of telitacicept in the treatment of immunocompromised and refractory lupus nephritis.Frontiers in immunology · 2025Article
- Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol.Lupus science & medicine · 2024Article
- Social support and audience engagement of lupus-related posts on social networking sites in China.Heliyon · 2024Review
- The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines.Arthritis research & therapy · 2024Article
- Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.